These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. The Institute for One World Health--a not-for-profit pharmaceutical company. Lundberg GD MedGenMed; 2005 Jan; 7(1):61. PubMed ID: 16369366 [No Abstract] [Full Text] [Related]
6. Reader's response to the webcast video editorial entitled "the institute for one world health--a not-for-profit pharmaceutical company". Tarzwell R MedGenMed; 2005 Feb; 7(1):34. PubMed ID: 16369339 [No Abstract] [Full Text] [Related]
7. New non-profit organization will support research to combat neglected diseases. Walgate R Bull World Health Organ; 2002; 80(10):842-3. PubMed ID: 12471410 [No Abstract] [Full Text] [Related]
8. Charities seek cut of drug royalties. Ledford H Nature; 2011 Jul; 475(7356):275-6. PubMed ID: 21776052 [No Abstract] [Full Text] [Related]
9. Multiplexed point-of-care assays for HIV and co-infections for resource constrained settings: a perspective. Pai NP Future Microbiol; 2015; 10(9):1393-6. PubMed ID: 26346674 [No Abstract] [Full Text] [Related]
10. Busting the billion-dollar myth: how to slash the cost of drug development. Maxmen A Nature; 2016 Aug; 536(7617):388-90. PubMed ID: 27558048 [No Abstract] [Full Text] [Related]
11. Infectious diseases in Pakistan: a clear and present danger. Sultan F; Khan A Lancet; 2013 Jun; 381(9884):2138-40. PubMed ID: 23684256 [No Abstract] [Full Text] [Related]
12. Market opportunities and technology trends in point of care diagnostics - SMi conference. Shirvill J IDrugs; 2006 Apr; 9(4):263-5. PubMed ID: 16596479 [No Abstract] [Full Text] [Related]
13. Singapore. Novartis kicks off institute for neglected diseases. Normile D Science; 2003 Feb; 299(5608):811. PubMed ID: 12574598 [No Abstract] [Full Text] [Related]
14. Neglected diseases get vaccine research boost. Abbott A Nature; 2008 Feb; 451(7182):1037. PubMed ID: 18305506 [No Abstract] [Full Text] [Related]
15. Evidence-based point-of-care diagnostics: current status and emerging technologies. Chan CP; Mak WC; Cheung KY; Sin KK; Yu CM; Rainer TH; Renneberg R Annu Rev Anal Chem (Palo Alto Calif); 2013; 6():191-211. PubMed ID: 23527548 [TBL] [Abstract][Full Text] [Related]
16. Drugs and diagnostic innovations to improve global health. Peeling RW; Nwaka S Infect Dis Clin North Am; 2011 Sep; 25(3):693-705, xi. PubMed ID: 21896368 [TBL] [Abstract][Full Text] [Related]
17. Impact of non-profit organizations on drug discovery: opportunities, gaps, solutions. Matter A; Keller TH Drug Discov Today; 2008 Apr; 13(7-8):347-52. PubMed ID: 18405848 [TBL] [Abstract][Full Text] [Related]
18. Requirements for high impact diagnostics in the developing world. Urdea M; Penny LA; Olmsted SS; Giovanni MY; Kaspar P; Shepherd A; Wilson P; Dahl CA; Buchsbaum S; Moeller G; Hay Burgess DC Nature; 2006 Nov; 444 Suppl 1():73-9. PubMed ID: 17159896 [No Abstract] [Full Text] [Related]
19. Creative cross-organizational collaboration: coming to a project near you. Reeve BC Regen Med; 2012 Mar; 7(2):237-43. PubMed ID: 22236251 [TBL] [Abstract][Full Text] [Related]
20. Infectious Diseases of Poverty in Children: A Tale of Two Worlds. Hansen C; Paintsil E Pediatr Clin North Am; 2016 Feb; 63(1):37-66. PubMed ID: 26613688 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]